Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a report date of February 22, 2022. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Type | Instrument | Price (GBP) | Volume | Date |
|---|---|---|---|---|
| Acquisition (Option Exercise) | Ordinary Shares | 12.09 | 744 | 2022-02-18 |
| Sale | Ordinary Shares | 15.698 | 744 | 2022-02-18 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share transactions under the Company's ShareSave Plan involving the exercise of options granted on November 29, 2018, and a subsequent sale of shares by one executive.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of insider trading activity.
- Executives Involved: Mr. R. Connor (President, Vaccines and Global Health), Mr. D. Redfern (Chief Strategy Officer), Ms. D. Waterhouse (CEO, ViiV Healthcare), and Ms. V. Whyte (Company Secretary).
- Transaction Details: All acquisitions were made at an option price of £12.09 per share. Ms. D. Waterhouse subsequently sold 744 shares at £15.698 per share on the same day.
- Venue: London Stock Exchange (XLON).
Investor Verification Checklist
- Verify the total number of shares held by the named PDMRs post-transaction to assess their overall exposure.
- Confirm the terms of the ShareSave Plan options granted in November 2018 to understand the vesting schedule and exercise conditions.
- Review the market price of GSK shares on February 18, 2022, to contextualize the sale price of £15.698 relative to the market value.
- Check for any other concurrent filings (e.g., Form 20-F or press releases) for broader financial performance data not included in this specific transaction notice.